The influence of thermal and mechanical preparative techniques on the amorphous state of four poorly soluble compounds.
A number of studies in the literature have reported on the use of different preparative techniques to convert crystalline pharmaceutical compounds into the amorphous form. However, very few direct comparisons of different preparative techniques using the same drugs are available. The purpose of this study was to determine the influence of two techniques: quench cooling and ball milling on four structurally diverse pharmaceutical drugs. Dipyridamole, carbamazepine, glibenclamide, and indomethacin were converted to the amorphous form by (a) quench cooling of the drug melt and (b) ball milling. The chemical purity and physical form of the products was determined using diffractometric, spectroscopic, and thermal analytical techniques. Products were analysed immediately post preparation and after storage under different stability conditions. Quench cooling of the melt resulted in amorphous conversion of all four compounds. However with glibenclamide, quench cooling resulted in unacceptable chemical degradation whereas ball milling of glibenclamide resulted in a change in the keto-enol tautomerism at the aryl amide moiety of this drug. Ball milling resulted in predominantly amorphous products for all compounds except carbamazepine. Ball milling of carbamazepine resulted in a polymorphic transition of the starting material to form III. Physical stability studies showed that irrespective of preparative technique and storage conditions all samples showed at least partial reversion to the crystalline state after storage. Quench cooling of drug melts may be of use as a preparative technique however it can result in chemical degradation. Ball milling may also be of use as a preparative technique however its effectiveness is dependent on the unit cell structure of the compound.
Patterson
James E
JE
School of Pharmacy, University of Otago, PO Box 913, 9001 Dunedin, New Zealand.
James
Michael B
MB
Forster
Angus H
AH
Lancaster
Robert W
RW
Butler
James M
JM
Rades
Thomas
T
D002220:Carbamazepine / Q000737:chemistry*; D002626:Chemistry, Pharmaceutical; D003460:Crystallization; D004176:Dipyridamole / Q000737:chemistry*; D004355:Drug Stability; D005905:Glyburide / Q000737:chemistry*; D007213:Indomethacin / Q000737:chemistry*; D033362:Powder Diffraction; D012995:Solubility; D017550:Spectroscopy, Fourier Transform Infrared; D013678:Technology, Pharmaceutical / Q000379:methods; D013696:Temperature; D013818:Thermogravimetry; D014961:X-Ray Diffraction
D002220:Carbamazepine; D004176:Dipyridamole; D005905:Glyburide; D007213:Indomethacin